



Dear LDL-C Lowering Therapies Roundtable Participants,

Thank you for accepting the invitation to participate in the American College of Cardiology’s (ACC) virtual Heart House Roundtable titled “LDL-C Lowering Therapies: The Changing Lipid Landscape Roundtable” on Monday, July 27, 2020. As an esteemed participant, you are joining representatives from several medical specialty societies, industry, health systems, and other stakeholder groups to discuss challenges in lipid management. Your engagement in this initiative will help the American College of Cardiology (ACC) as we make strides toward improving patient outcomes.

The goal of this Roundtable is to address the practical issues and key clinical questions facing clinicians on the role and use of newer LDL-C lowering therapies in patients with ASCVD and high-risk primary prevention. Participants will also consider their role in therapy for patients with statin-associated side effects.

The aim of this meeting is not to reach consensus; we aim to uncover the challenges faced and hope to explore ideas of how the ACC can better serve clinicians and patients in managing dyslipidemia. Your valuable input will help to steer our work to support the broader community caring for high-risk patients with dyslipidemia and improve patient outcomes.

Heart House Roundtables are designed to encourage interactive and thoughtful discussion. As shown on the enclosed agenda, the day will be organized into two sessions. After brief presentations on each topic, participants will work together in small groups to review discussion questions through interactive breakout sessions, then reconvene to share their collective thoughts with the full group.

In preparation for the meeting, we have assembled briefing materials comprised of important information that we believe will provide essential background for discussion at the Roundtable. These materials also include the agenda and discussion questions. We hope that you will have the opportunity to familiarize yourself with these materials before the meeting to facilitate productive discussions.

On behalf of the ACC, we look forward to your participation and welcoming you to this virtual convening.

Sincerely,

**Pamela B. Morris, MD, FACC**  
Chair, LDL-C Lowering Therapies:  
The Changing Lipid Landscape

**Michael D. Shapiro, DO, MCR, FACC**  
Vice-Chair, LDL-C Lowering Therapies:  
The Changing Lipid Landscape

*President*

Athena Poppas, MD, FACC

*Vice President*

Dipti Itchhaporia, MD, FACC

*Immediate Past President*

Richard J. Kovacs, MD, MACC

*Treasurer*

Howard T. Walpole, Jr., MD, MBA, FACC

*Secretary and Board of Governors Chair*

Daniel M. Philbin, Jr. MD, FACC

*Board of Governors Chair-Elect*

Joseph E. Marine, MD, FACC

*Trustees*

Cathleen Biga, MSN, RN, FACC

Claire S. Duvernoy, MD, FACC

Edward T.A. Fry, MD, FACC

James L. Januzzi, Jr., MD, FACC

Jeffrey T. Kuvin, MD, FACC

Roxana Mehran, MD, FACC

Andrew P. Miller, MD, FACC

Daniel Jose Piñeiro, MD, FACC

*Interim Chief Executive Officer*

Cathleen C. Gates

*The mission of the American College of Cardiology and the American College of Cardiology Foundation is to transform cardiovascular care and improve heart health.*